Kura Oncology, Inc. (KURA): Price and Financial Metrics
GET POWR RATINGS... FREE!
KURA Stock Price Chart Interactive Chart >
KURA Price/Volume Stats
| Current price | $18.17 | 52-week high | $23.00 |
| Prev. close | $17.21 | 52-week low | $10.41 |
| Day low | $16.81 | Volume | 1,491,800 |
| Day high | $18.35 | Avg. volume | 760,465 |
| 50-day MA | $13.80 | Dividend yield | N/A |
| 200-day MA | $15.37 | Market Cap | 1.21B |
Kura Oncology, Inc. (KURA) Company Bio
Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. The company was founded in 2014 and is based in La Jolla, California.
Latest KURA News From Around the Web
Below are the latest news stories about Kura Oncology Inc that investors may wish to consider to help them evaluate KURA as an investment opportunity.
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2021 Results - Earnings Call TranscriptKura Oncology, Inc. (KURA) Q4 2021 Earnings Conference Call February 24, 2022, 4:30 PM ET Company Participants Troy Wilson – Chairman, Chief Executive Officer & President Tom Doyle – Senior Vice President of Finance and Accounting Pete De Spain – Vice President, Investor Relations & Corporate Communications Conference Call Participants... |
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML – – Multiple milestones and data readouts from KOMET-001 expected in 2022 – – First patients dosed in Phase 1/2 study of tipifarnib plus alpelisib in HNSCC – – Abstract supporting next-generation FTI program accepted for presentation at AACR – – $518 million in cash, cash equivalents and investments provide runway into 2024 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, |
Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial ResultsSAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial results after the close of U.S. financial markets on Thursday, February 24, 2022. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial resu |
Kura Oncology to Participate in SVB Leerink Global Healthcare ConferenceSAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 12:40 p.m. PT / 3:40 p.m. ET on Thursday, February 17, 2022. A live aud |
We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
KURA Price Returns
| 1-mo | 34.49% |
| 3-mo | 12.58% |
| 6-mo | 20.65% |
| 1-year | -18.30% |
| 3-year | -8.19% |
| 5-year | 111.28% |
| YTD | 29.79% |
| 2021 | -57.13% |
| 2020 | 137.53% |
| 2019 | -2.07% |
| 2018 | -8.24% |
| 2017 | 159.32% |
Loading social stream, please wait...